Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Rubenstein

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2022
Primary CNS Lymphoma: Progress With Dose-Intensive ConsolidationJames L Rubenstein
Leukemia & Lymphoma|September 7, 2018
Can rituximab unlock the innate potential of checkpoint blockade in the CNS?James L Rubenstein
Hematology. American Society of Hematology. Education Program|December 10, 2017
Biology of CNS lymphoma and the potential of novel agentsJames L Rubenstein
Hematology/Oncology Clinics of North America|November 28, 2016
The Challenge of Primary Central Nervous System LymphomaJulia Carnevale, James L Rubenstein
Chinese Clinical Oncology|April 6, 2015
New approaches in primary central nervous system lymphomaEleanor Fraser, Katherine Gruenberg, James L Rubenstein
Neurosurgical Focus|December 1, 2006
Molecular pathogenesis of primary central nervous system lymphomaCigall Kadoch, Patrick Treseler, James L Rubenstein
Hematological Oncology|June 9, 2020
On point in primary CNS lymphomaMazie Tsang, Joseph Cleveland, James L Rubenstein
Hematology/Oncology Clinics of North America|August 9, 2005
Pathology and genetics of primary central nervous system and intraocular lymphomaJames L Rubenstein, Patrick Treseler, Joan M O'Brien
Annals of Lymphoma|February 2, 2022
Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative reviewMazie Tsang, James L Rubenstein, Elisa Jacobsen Pulczynski
Leukemia & Lymphoma|October 26, 2022
Primary CNS lymphoma: update on molecular pathogenesis and therapyShirley S Mo, Joseph Cleveland, James L Rubenstein
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2022
Primary CNS Lymphoma: Progress With Dose-Intensive ConsolidationJames L Rubenstein
Leukemia & Lymphoma|September 7, 2018
Can rituximab unlock the innate potential of checkpoint blockade in the CNS?James L Rubenstein
Hematology. American Society of Hematology. Education Program|December 10, 2017
Biology of CNS lymphoma and the potential of novel agentsJames L Rubenstein
Hematology/Oncology Clinics of North America|November 28, 2016
The Challenge of Primary Central Nervous System LymphomaJulia Carnevale, James L Rubenstein
Chinese Clinical Oncology|April 6, 2015
New approaches in primary central nervous system lymphomaEleanor Fraser, Katherine Gruenberg, James L Rubenstein
Neurosurgical Focus|December 1, 2006
Molecular pathogenesis of primary central nervous system lymphomaCigall Kadoch, Patrick Treseler, James L Rubenstein
Hematological Oncology|June 9, 2020
On point in primary CNS lymphomaMazie Tsang, Joseph Cleveland, James L Rubenstein
Hematology/Oncology Clinics of North America|August 9, 2005
Pathology and genetics of primary central nervous system and intraocular lymphomaJames L Rubenstein, Patrick Treseler, Joan M O'Brien
Annals of Lymphoma|February 2, 2022
Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative reviewMazie Tsang, James L Rubenstein, Elisa Jacobsen Pulczynski
Leukemia & Lymphoma|October 26, 2022
Primary CNS lymphoma: update on molecular pathogenesis and therapyShirley S Mo, Joseph Cleveland, James L Rubenstein
Pageof 6